This study is currently not recruiting participants.

A Phase III randomized double-blinded study comparing the combination of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib to dabrafenib and placebo as first-line therapy in subjects with unresectable (Stage IIIC) or metastatic (Stage IV)

Study of Investigational Medications for Cancer Treatment

Not Recruiting
18 years - 100 years
All
Phase N/A

Brief description of study.

The purpose of this study is to test the safety of dabrafenib and trametinib and see how well they work together compared to dabrafenib alone.

Detailed description of study

The purpose of this study is to test the safety of dabrafenib and trametinib and see how well they work together compared to dabrafenib alone.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Melanoma
  • Age: 18 years - 100 years
  • Gender: All

The purpose of this study is to investigate the safety and effectiveness of two investigational medications used together, compared to one investigational medication used alone. This study focuses on patients with a certain type of cancer, although the specific type is not mentioned here.

Participants in this study will receive either both investigational medications or just one. The study will involve monitoring the safety and effects of these treatments on the participants. No specific procedures are detailed in the provided description.

  • Who can participate: Participants must meet age criteria and other key eligibility factors, which are not specified in the description.
  • Study details: Participants will receive either two investigational medications together or one investigational medication alone. The study will monitor the safety and effects of these treatments.
Updated on 19 Feb 2024. Study ID: 1205008721

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team